Switzerland’s Clinical Trial Regulatory Framework: Swissmedic, HRA, and ClinO

Switzerland runs one of the few developed clinical-research systems in Europe that sits entirely outside the European Union’s Clinical Trials Regulation. A trial conducted at a Swiss site needs two independent, parallel authorizations before it can start: one from Swissmedic, the national medicines regulator, and one from the cantonal ethics committee with jurisdiction over the lead site. Neither approval substitutes for the other, and the two reviews examine different questions. For a research administrator coordinating a multi-country protocol, that dual-track structure — combined with Switzerland’s non-membership in the EU/EEA and the EU Clinical Trials Information System (CTIS) — is the single most consequential operational fact about running a study in Switzerland.

What Is Swissmedic?

Swissmedic is the Swiss Agency for Therapeutic Products, the country’s national regulatory authority for human and veterinary medicinal products and medical devices. It operates as an independent public-law institution under the Federal Department of Home Affairs, funded through a mix of federal contributions and regulatory fees, and its remit covers marketing authorization, clinical trial authorization, market surveillance, and inspection of manufacturers and trial sites. Swissmedic is also a Standing Regulatory Member of the International Council for Harmonisation (ICH) — the body that develops the E6 Good Clinical Practice guideline used across the US, EU, Japan, and most other major regulatory systems — and ICH itself is headquartered in Geneva under Swiss law, which puts Swissmedic close to the center of the international standards process even though Switzerland runs its own separate national authorization track for trials.

The Legal Framework: HRA and ClinO

Clinical research on human subjects in Switzerland is governed by Swiss federal law, not by any EU instrument. The two governing texts are:

• The Human Research Act (HRA; German: Humanforschungsgesetz, HFG; SR 810.30) — the framework statute that sets out the general ethical and legal principles for research involving humans, human biological material, and health-related personal data, including the requirement for both ethics committee approval and, where applicable, regulatory authorization before a project can begin.
• The Clinical Trials Ordinance (ClinO; SR 810.305) — the implementing ordinance, in force since 1 January 2014, that translates the HRA’s principles into the specific procedural rules for clinical trials with medicinal products and medical devices: risk-based trial categorization, the respective competencies of Swissmedic and the ethics committees, application content, and review deadlines.

A companion ordinance, ClinO-MD, addresses clinical investigations of medical devices specifically, aligning Swiss device-trial rules with the EU Medical Device Regulation framework even though Switzerland sits outside the EU’s own regulatory perimeter for devices.

The Dual-Track Authorization System

This is the feature that most distinguishes Switzerland from single-authority systems like the FDA’s IND pathway or the EU’s centralized CTIS submission. ClinO splits review into two tracks that run independently and in parallel:

• Swissmedic reviews the scientific and pharmaceutical quality of the trial: the investigational product’s quality, safety data supporting the proposed use in humans, the trial design’s ability to answer its scientific question, and (for devices) compliance with the essential requirements under Switzerland’s Therapeutic Products Act.
• The cantonal ethics committee reviews the ethical acceptability of the research: the risk-benefit balance for participants, the informed consent process and materials, participant recruitment and vulnerable-population safeguards, and investigator and site suitability.

Because the two authorities examine different things, in principle one authority’s decision does not depend on or bind the other’s — a trial can, in theory, be authorized by one and rejected by the other, though sponsors coordinate submissions to avoid that outcome in practice. Applications go through BASEC (the Business Administration System for Ethics Committees), the shared online submission platform, and are coordinated nationally by swissethics, the umbrella organization for Switzerland’s cantonal and inter-cantonal ethics committees. For a multi-site trial, the sponsor designates a single lead ethics committee, which conducts the substantive ethical review on behalf of all sites; the ethics committees at the other participating sites review only site-specific matters, such as local investigator suitability and facilities.

Risk-Based Trial Categories: A, B, and C

ClinO assigns every clinical trial with a medicinal product to one of three risk categories, and the category determines whether Swissmedic authorization is required at all, alongside the ethics committee review that applies in every case:

• Category A (lowest risk) — trials using a medicinal product already authorized in Switzerland and used within the terms of its approved product information. These trials are exempt from Swissmedic authorization; a notification to Swissmedic is required instead, while cantonal ethics committee approval is still mandatory.
• Category B (standard risk) — the largest group in practice, covering most investigational-product trials and any trial using an authorized product outside its approved indication, dose, or population. Category B trials require full authorization from both Swissmedic and the ethics committee.
• Category C (highest risk) — trials presenting the greatest uncertainty or risk to participants, such as first-in-human studies or trials with products not yet authorized anywhere. These require the most rigorous joint review from both authorities. (For medical device investigations specifically, ClinO-MD further subdivides high-risk review into C1–C3 based on CE-marking status; that subdivision does not apply to medicinal-product trials.)

How the Authorization Process Works

In practice, a sponsor planning a Swiss trial site works through roughly this sequence:

1. Determine the trial category (A, B, or C) under ClinO, since this drives which Swissmedic pathway applies and what the application dossier must contain.
2. Submit via BASEC to the designated lead cantonal ethics committee. For Category B and C medicinal-product trials, the sponsor submits to Swissmedic at the same time, so the two reviews proceed in parallel rather than sequentially.
3. Respond to a completeness/deficiency check. The ethics committee confirms receipt and flags any missing information within 7 days for medicinal-product trials (10 days for medical-device trials).
4. Await the substantive decision. The ethics committee’s statutory decision period is 30 days for medicinal-product trials (extended to 45 days for multi-centre medicinal-product trials) and 40 days for medical-device trials, running from confirmation that the dossier is complete. Swissmedic’s own scientific review runs on its own statutory clock in parallel, per ClinO.
5. Both authorizations must be in hand before enrollment begins at any Swiss site, and any subsequent substantial amendment to the protocol, investigational product, or consent materials generally requires re-review by both authorities before it takes effect.

A May 2026 pilot — the FAST-Track initiative — lets Category B and C medicinal-product trials that first secure an accelerated-review confirmation from Swissmedic also receive accelerated evaluation from the corresponding ethics committee, tightening the coordination between the two tracks for sponsors who opt in.

Switzerland vs. the EU: A Genuinely Separate Track

Switzerland is not a member of the EU or the EEA, and Swiss sites do not participate in the EU’s Clinical Trials Regulation (Regulation (EU) 536/2014) or its single-submission portal, CTIS. A sponsor running a multinational trial that includes Switzerland cannot simply add a Swiss site to a CTIS submission; Switzerland has to be managed as a fully separate national authorization, filed directly with Swissmedic and the relevant Swiss ethics committee, on Swiss timelines, under the HRA and ClinO rather than the EU CTR. That is a materially different operational burden than adding, say, a second EU member state to an existing CTIS application.

The two systems are not unrelated, however. Switzerland and the EU maintain a bilateral Mutual Recognition Agreement covering conformity assessment, including the mutual acceptance of GMP inspection results and manufacturing authorizations for medicinal products — which reduces duplicate manufacturing-quality inspections even though it does not extend to clinical trial authorization itself. Both systems also converge on the same underlying scientific and ethical standard: ICH E6 Good Clinical Practice governs trial conduct in both Switzerland and the EU, so a site running to GCP standard is largely running to the same conduct standard regardless of which authorization track approved it. For background on that shared standard, see CASRAI’s guide to Good Clinical Practice (GCP) and the ICH GCP dictionary entry; for how the EU’s own centralized system compares to a single-authority model, see EMA vs. FDA.

Switzerland in the Wider International Pathway Landscape

Switzerland’s dual-track, ethics-committee-plus-regulator model has more in common structurally with Canada’s clinical trial framework — where Health Canada’s Clinical Trial Application review and Research Ethics Board (REB) approval likewise proceed as two distinct, independently governed reviews — than with single-portal systems. Research administrators who already coordinate parallel Health Canada/REB submissions for Canadian sites will recognize the same basic operational discipline in Switzerland: track two independent clocks, two independent dossiers, and two independent approval letters, and don’t assume progress on one implies progress on the other.

Frequently Asked Questions

Does a Swissmedic authorization also cover ethics approval, or vice versa?

No. They are legally independent authorizations reviewing different questions — scientific/pharmaceutical quality for Swissmedic, ethical acceptability for the cantonal ethics committee — and a trial needs both (except Category A trials, which need ethics committee approval plus a Swissmedic notification rather than full Swissmedic authorization).

What is BASEC?

BASEC (Business Administration System for Ethics Committees) is the shared online platform sponsors use to submit clinical trial applications to Switzerland’s cantonal ethics committees, coordinated nationally by swissethics.

Can a sponsor use the EU’s CTIS portal to add a Swiss trial site?

No. Switzerland is outside the EU/EEA and does not participate in CTIS or the EU Clinical Trials Regulation. A Swiss site requires a fully separate national submission to Swissmedic and the relevant cantonal ethics committee under the HRA and ClinO.

How many ethics committees review a multi-site Swiss trial?

One lead cantonal ethics committee conducts the substantive ethical review on behalf of all participating sites; committees at other sites review only local, site-specific matters such as investigator and facility suitability.

Which trials are exempt from Swissmedic authorization?

Category A trials — those using a medicinal product already authorized in Switzerland, within the terms of its approved product information — require only a notification to Swissmedic rather than full authorization, though cantonal ethics committee approval is still required.